Literature DB >> 12630658

Combining lithium and anticonvulsants in bipolar disorder: a review.

Ronald Pies1.   

Abstract

While the benefits of lithium in bipolar disorder are evident, its limitations as monotherapy are well recognized, particularly in bipolar depression. This has propelled trials of combined lithium-anticonvulsant therapy in many bipolar patients. The present review of the English-language literature examines both controlled and open studies of such combination therapy, including the risk of drug-drug interactions. Trials of lithium plus either carbamazepine or divalproex have generally produced favorable results, although increased rates of adverse effects may reduce treatment adherence. More recent reports suggest that lithium may be safely and effectively combined with lamotrigine, and perhaps with topiramate, although controlled studies are required. The combined use of lithium with newer, putative mood stabilizers, such as zonisamide or levetiracetam, cannot yet be recommended, but is an important area for future research. Provisional recommendations for combined treatment are provided.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12630658     DOI: 10.1023/a:1021969001231

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  9 in total

1.  Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism.

Authors:  Sandra Ghelardoni; Richard P Bazinet; Stanley I Rapoport; Francesca Bosetti
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

2.  GSK3β inhibition accelerates axon debris clearance and new axon remyelination.

Authors:  Yixun Chen; Jian Weng; Duanyang Han; Bo Chen; Mingtai Ma; Youlai Yu; Ming Li; Zhongdi Liu; Peixun Zhang; Baoguo Jiang
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

3.  Lithium enhances remyelination of peripheral nerves.

Authors:  Joelle Makoukji; Martin Belle; Delphine Meffre; Ruth Stassart; Julien Grenier; Ghjuvan'Ghjacumu Shackleford; Robert Fledrich; Cosima Fonte; Julien Branchu; Marie Goulard; Catherine de Waele; Frédéric Charbonnier; Michael W Sereda; Etienne-Emile Baulieu; Michael Schumacher; Sophie Bernard; Charbel Massaad
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-21       Impact factor: 11.205

4.  Lithium-mediated protection against ethanol neurotoxicity.

Authors:  Jia Luo
Journal:  Front Neurosci       Date:  2010-06-28       Impact factor: 4.677

Review 5.  Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 6.  Drug Interactions with Lithium: An Update.

Authors:  Patrick R Finley
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

7.  Brain choline concentrations may not be altered in euthymic bipolar disorder patients chronically treated with either lithium or sodium valproate.

Authors:  Ren H Wu; Tina O'Donnell; Michele Ulrich; Sheila J Asghar; Christopher C Hanstock; Peter H Silverstone
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-07-30

8.  Case Report: A Case of Valproic Acid-Induced Hyperammonemic Encephalopathy Associated With the Initiation of Lithium: A Re-duplicable Finding.

Authors:  Anna Levy; Etienne Very; François Montastruc; Philippe Birmes; Adeline Jullien; Louis Richaud
Journal:  Front Psychiatry       Date:  2022-05-02       Impact factor: 4.157

9.  Psychopharmacology of topiramate: from epilepsy to bipolar disorder.

Authors:  Marco Mula; Andrea E Cavanna; Francesco Monaco
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.